Krzysztof Schwermer
Poznan University of Medical Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Krzysztof Schwermer.
BioMed Research International | 2015
Krzysztof Pawlaczyk; Ewa Baum; Krzysztof Schwermer; Krzysztof Hoppe; Bengt Lindholm; Andrzej Breborowicz
Experimental animal models improve our understanding of technical problems in peritoneal dialysis PD, and such studies contribute to solving crucial clinical problems. We established an acute and chronic PD model in nonuremic and uremic rats. We observed that kinetics of PD in rats change as the animals are aging, and this effect is due not only to an increasing peritoneal surface area, but also to changes in the permeability of the peritoneum. Changes of the peritoneal permeability seen during chronic PD in rats are comparable to results obtained in humans treated with PD. Effluent dialysate can be drained repeatedly to measure concentration of various bioactive molecules and to correlate the results with the peritoneal permeability. Additionally we can study in in vitro conditions properties of the effluent dialysate on cultured peritoneal mesothelial cells or fibroblasts. We can evaluate acute and chronic effect of various additives to the dialysis fluid on function and permeability of the peritoneum. Results from such study are even more relevant to the clinical scenario when experiments are performed in uremic rats. Our experimental animal PD model not only helps to understand the pathophysiology of PD but also can be used for testing biocompatibility of new PD fluids.
Archives of Medical Science | 2016
Krzysztof Hoppe; Krzysztof Schwermer; Anna Kawka; Patrycja Klysz; Ewa Baum; Malgorzata Kaluzna; Dorota Sikorska; Anna Scigacz; Bengt Lindholm; Krzysztof Pawlaczyk; Andrzej Oko
Introduction Body mass decomposition and hydration state imbalances affect patients on maintenance dialysis. We compared body composition, hydration and nutritional state of patients on peritoneal dialysis (PD) and hemodialysis (HD) based on dialysis vintage (DV). Material and methods Three hundred and fifty-nine prevalent patients on HD (n = 301) and PD (n = 58) were divided into 3 subgroups depending on DV: < 2 years HD (n = 41) and PD (n = 28), 2–4 years HD (n = 111) and PD (n = 17), > 4 years HD (n = 149) and PD (n = 13). Bioimpedance analysis delivered data including overhydration (OH), Lean (LTM) and adipose lipids mass (FAT). Other measurements included daily diuresis (DD), subjective global assessment (SGA) and serum albumin (alb), C-reactive protein (CRP) and total cholesterol (TChol), and hemoglobin (Hb). Results Dialysis vintage < 2 years. Hemodialysis patients were older (65.5 ±18.5 vs. 50.9 ±17.1; p < 0.01) with a higher mortality (28 vs. 1; p < 0.01) and OH (8.0 ±4.3 vs. 1.6 ±3.1; p < 0.001). Hemoglobin (10.6 ±1.5 vs. 11.8 ±1.7; p < 0.05), TChol (180.2 ±47.0 vs. 211.7 ±46.3; p < 0.05), DD (871 ±729 vs. 1695 ±960; p < 0.001) and LTM (46.5 ±12.9 vs. 53.8 ±14.4; p < 0.05) were lower on HD. Dialysis vintage 2–4 years: when compared to PD, HD patients had higher OH (11.7 ±5.9 vs. 2.1 ±3.2; p < 0.001) and lower Hb (10.8 ±1.5 vs. 11.9 ±1.4; p < 0.01). Dialysis vintage > 4 years: compared to PD, HD patients had higher LTM (44.3 ±11.7 vs. 38.6 ±7.9; p < 0.05) and lower FAT (34.4 ±11.1 vs. 42.8 ±6.4; p < 0.01). Conclusions Dialysis patients’ body composition depends on dialysis modality and DV. Dialysis vintage < 2 years is associated with better hydration, nutritional state, and survival in PD patients, but longer DV reduces these benefits. Dialysis vintage > 4 years associated with similar hydration and mortality in both PD and HD while body composition was better on HD.
The Scientific World Journal | 2014
Maria Wanic-Kossowska; Bartlomiej Posnik; Mikołaj Kobelski; Elżbieta Pawliczak; Krzysztof Pawlaczyk; Krzysztof Hoppe; Krzysztof Schwermer; Dorota Sikorska
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most frequently occurring autosomal diseases inherited in the dominant manner. Due to this, lesions in the cardiovascular system of ADPKD patients have caught the attention of clinical investigators worldwide. The aim of the study was to analyse cardiovascular complications in ADPKD patients with a focus on left ventricular hypertrophy (LVH) and selected components of its systolic/diastolic function based on echocardiography. The study was conducted on 55 patients with ADPKD (24 males, 31 females), subdivided into three groups according to the stage of chronic kidney disease (CKD). The patient group with ADPKD and ESRD (group C) manifested an increased incidence of the D allele as compared to group A and group B (χ 2 = 4.217, P = 0.04). In all ADPKD patients with the DD genotype, left ventricular mass (LVM), posterior wall thickness (PWT), and interventricular septal thickness (IVS) were significantly higher compared to patients possessing the II and ID genotypes (P < 0.02, P < 0.003, and P < 0.009, resp.). The DD genotype exists more frequently in ADPKD patients with ESRD and is associated with a higher occurrence of LVH and disturbances in systolic-diastolic function when compared to ADPKD ESRD patients with the II and ID genotypes.
Case reports in nephrology | 2013
Bartlomiej Posnik; Dorota Sikorska; Krzysztof Hoppe; Krzysztof Schwermer; Krzysztof Pawlaczyk; Andrzej Oko
Atypical hemolytic-uremic syndrome (aHUS), unlike typical HUS, is not due to bacteria but rather to an idiopathic or genetic cause that promotes dysregulation of the alternative complement pathway. It leads to hemolytic anemia, thrombocytopenia, and renal impairment. Although aHUS secondary to a genetic mutation is relatively rare, when occurring due to a mutation in Factor H (CFH), it usually presents with younger onset and has a more severe course, which in the majority ends with end-stage renal failure. Paradoxically to most available data, our case features acute aHUS due to a CFH mutation with late onset (38-year-old) and rapid progression to end-stage renal disease. Due to current data indicating a high risk of graft failure in such patients, the diagnosis of aHUS secondary to a genetic cause has disqualified our patient from a living (family) donor renal transplantation and left her with no other option but to begin permanent renal replacement therapy.
Blood Purification | 2015
Krzysztof Hoppe; Krzysztof Schwermer; Patrycja Klysz; Dorota Radziszewska; Peter Sawatiuk; Ewa Baum; Jolanta Kaczmarek; Magdalena Roszak; Malgorzata Kaluzna; Bengt Lindholm; Krzysztof Pawlaczyk; Andrzej Oko
Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine | 2015
Krzysztof Schwermer; Krzysztof Hoppe; Dorota Radziszewska; Patrycja Klysz; Peter Sawatiuk; Justin Nealis; Malgorzata Kaluzna; Jolanta Kaczmarek; Ewa Baum; Bengt Lindholm; Krzysztof Pawlaczyk; Andrzej Oko
Advances in Clinical and Experimental Medicine | 2017
Krzysztof Hoppe; Krzysztof Schwermer; Anna Olewicz-Gawlik; Patrycja Klysz; Anna Kawka; Ewa Baum; Dorota Sikorska; Katarzyna Ścigacz; Magdalena Roszak; Bengt Lindholm; Krzysztof Pawlaczyk; Andrzej Oko
Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine | 2016
Małgorzata Kałużna; Krzysztof Hoppe; Krzysztof Schwermer; Aisha Y. Ibrahim; Krzysztof Pawlaczyk; Katarzyna Ziemnicka
Polish archives of internal medicine | 2017
Małgorzata Kałużna; Krzysztof Hoppe; Krzysztof Schwermer; Aisha Y. Ibrahim; Krzysztof Pawlaczyk; Katarzyna Ziemnicka
Nephrology Dialysis Transplantation | 2017
Krzysztof Hoppe; Anna Szalek; Krzysztof Schwermer; Katarzyna Kryszan; Anna Kawka; Marta Olszewska; Ewa Baum; Krzysztof Pawlaczyk; Andrzej Oko